Category Archives: Partnerships

Free access to PharmScreen for COVID-19 research

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 has spread to all countries without exception, affecting not only risk-population but also young people and healthy individuals. At Pharmacelera we want to join the different public and private initiatives to find a treatment that can stop the expansion of the virus. To do so,…
Read more

IDIBELL and Pharmacelera sign a research agreement to find new drugs with anticancer applications

Researchers at Bellvitge Biomedical Research Institute will develop a research project with the company Pharmacelera to look for new molecules that block the cohesin complex, with applications in several difficult-to-treat cancers, such as myeloid leukemia, glioblastomas, Ewing sarcomas, colon cancer and bladder cancer. The cell cycle research group of the Bellvitge Biomedical Research Institute (IDIBELL),…
Read more

Machine Learning partnership to accelerate discovery of novel drugs

CCDC and Pharmacelera combine virtual screening and machine learning expertise to help scientists accelerate drug discovery Barcelona and Cambridge, UK, 26th June 2019. The Cambridge Crystallographic Data Centre (CCDC) and Pharmacelera have reached an agreement to perform a joint research project to reinforce the results obtained by structure-based in-silico technologies via ligand-based tools. GOLD, CCDC’s docking software used…
Read more

Agreement with CNIO for drug discovery in oncology

The Spanish National Research Centre (CNIO) is a Spanish public institution focused on the research, diagnosis and treatment of cancer. The CNIO is positioned within the top 10 ranking of research centres dedicated to cancer research worldwide (Scimago; Nature Index) and covers the whole R+D+I process, from basic up to clinical research to translate their…
Read more